Amylin Loses Preliminary Round of Lilly Fight over Byetta
Amylin Pharmaceutical Inc. lost its preliminary bid to block Eli Lilly and Co. from jointly promoting diabetes drugs Byetta and Tradjenta, but its underlying challenge to Lilly's marketing strategy has yet to get its day in court.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter